Way to go cali! People need their medicine, especially now more then ever. Stick together and be safe!! As San Franciscans continue to grapple with the magnitude of the
Way to go cali! People need their medicine, especially now more then ever. Stick together and be safe!! As San Franciscans continue to grapple with the magnitude of the "shelter in place" order issued simultaneously by six Bay Area counties on Monday, news that marijuana dispensaries and delivery services would not be considered an "essential" service by the city resulted in confusion and pushback. The decision was initially met with shock and outrage by prominent cannabis industry figures and consumers alike. However, the classification was reversed in under 24 hours Tuesday. In an email to anxious members of the industry sent Tuesday, as a joint effort between San Francisco’s Office of Cannabis and Department of Health, city officials acknowledged the request from the Mayor’s Office and the County Health Officer to shut down all cannabis businesses as a result of the "shelter in place" order. "The situation is fluid," the note conceded, "and we are working closely with city partners and healthcare professionals to craft a strategy that will allow for access to healthy and safe product. We are hopeful that this will create a pathway for businesses to support those that need access. Please standby." This last-minute effort to stock up on flower, vapes, tinctures and more comes in stark contrast to fellow “shelter in place” counties like Alameda, where cannabis stores will reportedly remain open for curbside pick-up and delivery for the duration of the order. Elsewhere, Massachusetts, Pennsylvania, and New Jersey have all made various assurances on behalf of their cannabis markets as well. Earlier in the day, one of the first organizations to condemn San Francisco’s decision to omit cannabis as an essential service was the California chapter of the National Organization for the Reform of Marijuana Laws. In a press release issued Tuesday, deputy director Ellen Komp emphasized the risk such unilateral closures could place on vulnerable medical patients. For recreational users, her argument questioned a rationale that permitted liquor sales but not the equally legal sale of cannabis (though dedicated liquor stores remain shuttered).
Well, we have to win something once in awhile, right!?!? i’ll take that any day!!! Federal agriculture officials are dropping the requirement that all THC testing on hemp crops must be performed at laboratories registered with the U.S. Drug Enforcement Administration, according to industry sources.

And food and drug regulators say it’s a “fool’s errand” to get people to stop taking over-the-counter CBD.

Greg Ibach, undersecretary for the U.S. Department of Agriculture told members at the National Association of State Departments of Agriculture (NASDA) meeting in Arlington, Virginia, that the USDA and DEA have reached an agreement to remove the requirement for hemp farmers to have their crops tested in DEA-registered laboratories.

The DEA requirement was included in the interim final rule for domestic hemp production that the USDA released Oct. 31. “This about-face by the USDA means that farmers can continue to use their trusted local and regional analytical testing labs to ensure compliance with USDA rules,” Josh Schneider, CEO of San Diego-based young plant producer Cultivaris Hemp, told Hemp Industry Daily.
“Getting rid of this ridiculous DEA testing requirement is a step in the right direction by the USDA,” he added. “Hopefully this means that the USDA has come to their senses and will be making better and smarter rules going forward.” Widespread opposition

The USDA received more than 4,700 comments about its hemp rules, Ibach told NASDA members.

Many of the comments took issue with the DEA testing requirement.

There are 47 laboratories currently registered with the DEA, and many states do not have a registered testing facility, which would require state, tribal and federal law enforcement agents responsible for testing hemp crops to send samples from out of state within a tight, 15-day testing window.

William Richmond, director of the USDA’s Domestic Hemp Production program, told farmers at the Industrial Hemp Summit in Virginia on Monday that testing and sampling requirements were among the aspects the agency could change.

Other parts of the rule, such as a 0.3% total THC limit and the requirement for information sharing, can be changed only by
Well, we have to win something once in awhile, right!?!? i’ll take that any day!!! Federal agriculture officials are dropping the requirement that all THC testing on hemp crops must be performed at laboratories registered with the U.S. Drug Enforcement Administration, according to industry sources. And food and drug regulators say it’s a “fool’s errand” to get people to stop taking over-the-counter CBD. Greg Ibach, undersecretary for the U.S. Department of Agriculture told members at the National Association of State Departments of Agriculture (NASDA) meeting in Arlington, Virginia, that the USDA and DEA have reached an agreement to remove the requirement for hemp farmers to have their crops tested in DEA-registered laboratories. The DEA requirement was included in the interim final rule for domestic hemp production that the USDA released Oct. 31. “This about-face by the USDA means that farmers can continue to use their trusted local and regional analytical testing labs to ensure compliance with USDA rules,” Josh Schneider, CEO of San Diego-based young plant producer Cultivaris Hemp, told Hemp Industry Daily. “Getting rid of this ridiculous DEA testing requirement is a step in the right direction by the USDA,” he added. “Hopefully this means that the USDA has come to their senses and will be making better and smarter rules going forward.” Widespread opposition The USDA received more than 4,700 comments about its hemp rules, Ibach told NASDA members. Many of the comments took issue with the DEA testing requirement. There are 47 laboratories currently registered with the DEA, and many states do not have a registered testing facility, which would require state, tribal and federal law enforcement agents responsible for testing hemp crops to send samples from out of state within a tight, 15-day testing window. William Richmond, director of the USDA’s Domestic Hemp Production program, told farmers at the Industrial Hemp Summit in Virginia on Monday that testing and sampling requirements were among the aspects the agency could change. Other parts of the rule, such as a 0.3% total THC limit and the requirement for information sharing, can be changed only by
Funded by U.S. company Cannabics Pharmaceuticals, a firm focused on the development of cannabinoid therapies for cancer treatment, Israeli researchers have demonstrated the anti-tumor efficacy of CBG and CBC against human gastrointestinal cancer cell lines.

SUBSCRIBE
January 27, 2020
Posted by Andrea Sparr-Jaswa
International Medical Cannabis News
TEL AVIV, Israel and BETHESDA, Maryland, Jan. 27, 2020 /PRNewswire/PRESS RELEASE -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that in a series of tests conducted at the company's High Through-put Screening (HTS) facility in Israel, it has been shown that the cannabinoids CBC (cannabichromene) and CBG (cannabigerol) both exhibit anti-tumor properties, tested on human gastrointestinal cancer cells.

CBC is an additional non-intoxicating cannabinoid and is one of the naturally occurring phytocannabinoids. It bears a host of potential positive therapeutic qualities and may promote antimicrobial, anti‐inflammatory, analgesic, and neurogenesis activity. It is particularly found in younger cannabis plants, albeit in small quantities. 
In these tests, the HTS platform was utilized to screen the necrotic effects of a variety of cannabinoids on human gastrointestinal cancer cells, in addition to other cancer types previously tested. CBC and CBG were both shown to induce significantly higher rates of necrosis in these cancer cells compared to other cannabinoids, thus strengthening previously obtained results. © credit | Cannabics Pharmaceuticals
Cannabinoid extract causing necrosis in gastrointestinal cancer cell line. The Yellow color is a marker for necrosis. On the right - control, on the left – after treatment with cannabinoids
Dr. Yaakov Waksman, the company's head of cannabinoid research, said,
Funded by U.S. company Cannabics Pharmaceuticals, a firm focused on the development of cannabinoid therapies for cancer treatment, Israeli researchers have demonstrated the anti-tumor efficacy of CBG and CBC against human gastrointestinal cancer cell lines. SUBSCRIBE January 27, 2020 Posted by Andrea Sparr-Jaswa International Medical Cannabis News TEL AVIV, Israel and BETHESDA, Maryland, Jan. 27, 2020 /PRNewswire/PRESS RELEASE -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that in a series of tests conducted at the company's High Through-put Screening (HTS) facility in Israel, it has been shown that the cannabinoids CBC (cannabichromene) and CBG (cannabigerol) both exhibit anti-tumor properties, tested on human gastrointestinal cancer cells. CBC is an additional non-intoxicating cannabinoid and is one of the naturally occurring phytocannabinoids. It bears a host of potential positive therapeutic qualities and may promote antimicrobial, anti‐inflammatory, analgesic, and neurogenesis activity. It is particularly found in younger cannabis plants, albeit in small quantities. In these tests, the HTS platform was utilized to screen the necrotic effects of a variety of cannabinoids on human gastrointestinal cancer cells, in addition to other cancer types previously tested. CBC and CBG were both shown to induce significantly higher rates of necrosis in these cancer cells compared to other cannabinoids, thus strengthening previously obtained results. © credit | Cannabics Pharmaceuticals Cannabinoid extract causing necrosis in gastrointestinal cancer cell line. The Yellow color is a marker for necrosis. On the right - control, on the left – after treatment with cannabinoids Dr. Yaakov Waksman, the company's head of cannabinoid research, said, "My working assumption is that these results show that a correlation may exist between a cannabinoid's Topological Polar Surface Area (TPSA) value and its ability to induce anti-tumor activity, diminishing cancer cell's viability rates. CBC and CBG, as neutral cannabinoids, were both found to have a TPSA value which allows t